<DOC>
	<DOCNO>NCT00658086</DOCNO>
	<brief_summary>To evaluate safety , tolerability antiviral activitity ALN-RSV01 RSV infect lung transplant patient</brief_summary>
	<brief_title>Phase 2 Study ALN-RSV01 Lung Transplant Patients Infected With Respiratory Syncytial Virus ( RSV )</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Single bilateral lung transplant recipient Confirmed RSV infection Greater 90 day post current lung transplant Rejection free minimum 1 month Antimicrobial therapy know viral , bacterial , fungal respiratory coinfection time diagnosis Bronchiolitis obliterans syndrome ( BOS ) Grade 3 state BOS FEV1 stable least 3 month Use alemtuzumab within 9 month prior screen ; antithymocyte globulin ( ATG ) thymoglobulin within 3 month screen : concurrent use &gt; = 0.3 mg/kg/day prednisone equivalent maintenance therapy active treament acute graft rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>ALN-RSV01</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>